A Phase 1/2 interventional study of MS-553 and MS-553 in Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma and Aggressive Lymphoma, sponsored by MingSight Pharmaceuticals, Inc. Terminated at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-10.
Sponsored by MingSight Pharmaceuticals, Inc · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States — 138 open to participants now, 252 under way, 34 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · United States.
Among the 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States, this one is the 393rd largest by enrollment of the 1,298 interventional ones that give a count, is one of 40 that started in 2018, is one of 172 in phase 1/2, and was the 1,197th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →138 of the 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States are open now. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+
Roswell Park Cancer Institute · Sites in United States
Ages 18+
Jennifer Woyach · Sites in United States
Ages 18+
Nurix Therapeutics, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,501 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 657 · Phase 2 724 · Phase 3 120 · Phase 4 6
First in 1986; this study’s year is marked. 40 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 36 across the 1,298 interventional studies, 135 across the 91 observational. Of the 1,167 that completed or were terminated, 470 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
398 of 1,501 have an industry lead sponsor. The 10 most frequent:
MingSight Pharmaceuticals, Inc is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
MingSight Pharmaceuticals, Inc has 3 studies filed under Leukemia, Lymphocytic, Chronic, B-Cell — fewer than ten, so there is no comparison to draw.
83 of the studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT03836261Phase 3Acerta Pharma BVStudy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | 2027-04-30 |
| NCT05624554Phase 3Merck Sharp & Dohme LLCA Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) | 2027-05-19 |
| NCT05057494Phase 3AstraZenecaA Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | 2027-07-15 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
Add all 83 to your calendar (.ics) → With an account.
Among the 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase I/II Dose-Escalation and Expansion Study Of The Selective PKC-Β Inhibitor MS-553 In Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be eligible for inclusion in the primary escalation and expansion cohort 1 in this study, patients must meet all of the following criteria:
Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL):
Exclusion Criteria:
Patients who meet any of the following criteria are not eligible for the primary escalation and expansion cohorts of this study:
Any of the following prior therapies within 14 days prior to cycle 1, day 1:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
R/R CLL/SLL patients
Drug: MS-553
R/R CLL/SLL patients
Drug: MS-553
patients with aggressive lymphoma
Drug: MS-553
BTK inhibitor naïve CLL/SLL patients
Drug: MS-553 · Drug: acalabrutinib
BTK inhibitor naïve CLL/SLL patients
Drug: MS-553 · Drug: acalabrutinib
BTK inhibitor naïve CLL/SLL patients with certain gene mutations
Drug: MS-553 · Drug: acalabrutinib
Bcl-2 inhibitor naïve CLL/SLL patients
Drug: MS-553 · Drug: venetoclax · Drug: Rituximab · Drug: obinutuzumab
Bcl-2 inhibitor naïve CLL/SLL patients
Drug: MS-553 · Drug: venetoclax · Drug: Rituximab · Drug: obinutuzumab
Oral, multiple dose levels
Oral recommended phase 2 dose of MS-553
Oral
Oral
Also known as: Venclexta, Venclyxto
IV
Also known as: Rituxan, MabThera
IV
Also known as: Gazyva
The Incidence Rate of DLT and TEAE Requiring Study Drug Discontinuation
DLT are defined as any of the following treatment-emergent events occurring during the DLT evaluation period. 1. Death 2. Hematologic toxicities: • Grade 4 neutropenia for ≥ 7 days • Grade 3 febrile neutropenia: absolute neutrophil count (ANC) 38.3°C (101°F) or a sustained temperature ≥38°C (100.4°F) for \> 1 hour • Grade 4 thrombocytopenia ≥ 14 days (patients with baseline platelet count of ≥ 50 x 109 /L) • Grade 4 thrombocytopenia ≥ 28 days (patients with baseline platelet count \< 50 x 10 9 /L) • ≥ Grade 3 thrombocytopenia associated with ≥ Grade 2 hemorrhage • New ≥ Grade 3 anemia requiring transfusion in a patient previously transfusion independent. 3. Nonhematologic toxicities: • Any other ≥ Grade 3 toxicity not reversed to any one of the following three conditions in 7 days with appropriate intervention: a) baseline; b) \< Grade 1; or c) a status considered to be controlled by the SRC. • Any TEAE requiring \>25% of doses of scheduled study drug to be withheld during the DLT period
Time frame: Assessments for DLT and TEAE will occur during Cycle 1 (28 days) for A1 Cohort and B1 Cohort and Cycles 1-4 (up to 112 days) for C1 Cohort.
The ORR of MS-553 in Patients With CLL/SLL Whose Disease Relapsed After or Was Refractory to at Least One Prior Therapy
This will be assessed according to the 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Response Criteria with modifications for treatment-related lymphocytosis. Any patient who receives at least one cycle of study therapy is evaluable for response.
Time frame: Evaluation of the efficacy endpoints related to response will incorporate the data from the first 9 cycles (up to 252 days) of treatment.
Participants enrolled between May 2018 and Oct. 2023
| Milestone | Phase I Dose Escalation Cohort A1 (MS-553:100 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 200 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 250 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 300 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 350 mg BID) | Phase II Expansion Cohort A2 (MS-553 Monotherapy) | Phase II Expansion Cohort A3 (MS-553 Monotherapy) | Phase I Combination Dose Escalation Cohort B1 (MS-553: 150 mg BID) | Phase I Combination Dose Escalation Cohort B1 (MS: 553: 200 mg BID) | Phase I Combination Dose Escalation Cohort C1 (MS-553: 150 mg BID) | Phase I Combination Dose Escalation Cohort C1 (MS-553: 200 mg BID) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 4 | 3 | 3 | 4 | 4 | 0 | 0 | 3 | 3 | 3 | 4 |
| Completed | 3 | 3 | 3 | 3 | 3 | 0 | 0 | 3 | 3 | 3 | 3 |
| Not completed | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Milestone | Phase I Dose Escalation Cohort A1 (MS-553:100 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 200 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 250 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 300 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 350 mg BID) | Phase II Expansion Cohort A2 (MS-553 Monotherapy) | Phase II Expansion Cohort A3 (MS-553 Monotherapy) | Phase I Combination Dose Escalation Cohort B1 (MS-553: 150 mg BID) | Phase I Combination Dose Escalation Cohort B1 (MS: 553: 200 mg BID) | Phase I Combination Dose Escalation Cohort C1 (MS-553: 150 mg BID) | Phase I Combination Dose Escalation Cohort C1 (MS-553: 200 mg BID) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 23 | 6 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 20 | 5 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 0 | 0 | 0 |
DLT are defined as any of the following treatment-emergent events occurring during the DLT evaluation period. 1. Death 2. Hematologic toxicities: • Grade 4 neutropenia for ≥ 7 days • Grade 3 febrile neutropenia: absolute neutrophil count (ANC) 38.3°C (101°F) or a sustained temperature ≥38°C (100.4°F) for \> 1 hour • Grade 4 thrombocytopenia ≥ 14 days (patients with baseline platelet count of ≥ 50 x 109 /L) • Grade 4 thrombocytopenia ≥ 28 days (patients with baseline platelet count \< 50 x 10 9 /L) • ≥ Grade 3 thrombocytopenia associated with ≥ Grade 2 hemorrhage • New ≥ Grade 3 anemia requiring transfusion in a patient previously transfusion independent. 3. Nonhematologic toxicities: • Any other ≥ Grade 3 toxicity not reversed to any one of the following three conditions in 7 days with appropriate intervention: a) baseline; b) \< Grade 1; or c) a status considered to be controlled by the SRC. • Any TEAE requiring \>25% of doses of scheduled study drug to be withheld during the DLT period
| Participants | Phase I Dose Escalation Cohort A1 (MS-553: 100mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 200mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 250mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 300mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 350mg BID) | Phase I Combination Dose Escalation Cohort B1 (MS-553: 150 mg BID) | Phase I Combination Dose Escalation Cohort B1 (MS-553-200 mg BID) | Phase I Combination Dose Escalation Cohort C1 (MS-553: 150 mg BID) | Phase I Combination Dose Escalation Cohort C1 (MS-553: 200 mg BID) |
|---|---|---|---|---|---|---|---|---|---|
| Number of participants with DLT | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Number of participants with TEAE | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
This will be assessed according to the 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Response Criteria with modifications for treatment-related lymphocytosis. Any patient who receives at least one cycle of study therapy is evaluable for response.
| percentage of participants | Cohort A1 (MS-553: 100 mg BID) | Cohort A1 (MS-553: 200 mg BID) | Cohort A1 (MS-553: 250 mg BID) | Cohort A1 (MS-553: 300 mg BID) | Cohort A1 (MS-553: 350 mg BID) | Cohort A2 (MS-553 Monotherapy) | Cohort A3 (MS-553 Monotherapy) | Phase I Combination Dose Escalation Cohort B1 (MS-553: 150 mg BID) | Phase I Combination Dose Escalation Cohort B1 (MS-553: 200 mg BID) | Phase I Combination Dose Escalation Cohort C1 (MS-553: 150 mg BID) | Phase I Combination Dose Escalation Cohort C1 (MS-553: 200 mg BID) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| The ORR of MS-553 in Patients With CLL/SLL Whose Disease Relapsed After or Was Refractory to at Least One Prior Therapy | 0 | 33.3 | 100 | 66.7 | 33.3 | 42.10 | 25 | 100 | 66.7 | 100 | 100 |
Collected over For the duration of the study drug treatment (up to 3 years). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase I Dose Escalation Cohort A1 (MS-553: 100 mg BID) | 1/4 (25%) | 2/4 (50%) | 4/4 (100%) |
| Phase I Dose Escalation Cohort A1 (MS-553: 200 mg BID) | 2/3 (66.7%) | 3/3 (100%) | 3/3 (100%) |
| Phase I Dose Escalation Cohort A1 (MS-553: 250 mg BID) | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| Phase I Dose Escalation Cohort A1 (MS-553: 300 mg BID) | 2/4 (50%) | 3/4 (75%) | 4/4 (100%) |
| Phase I Dose Escalation Cohort A1 (MS-553: 350 mg BID) | 2/4 (50%) | 3/4 (75%) | 4/4 (100%) |
| Phase II Expansion Cohort A2 (MS-553 Monotherapy) | 6/23 (26.1%) | 15/23 (65.2%) | 23/23 (100%) |
| Phase II Expansion Cohort A3 (MS-553 Monotherapy) | 3/6 (50%) | 3/6 (50%) | 6/6 (100%) |
| Phase I Combination Dose Escalation Cohort B1 (MS-553: 150 mg BID) | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Phase I Combination Dose Escalation Cohort B1 (MS-553: 200 mg BID) | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Phase I Combination Dose Escalation Cohort C1 (MS-553: 150 mg BID) | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Phase I Combination Dose Escalation Cohort C1 (MS-553: 200 mg BID) | 0/4 (0%) | 2/4 (50%) | 4/4 (100%) |
| Event | Phase I Dose Escalation Cohort A1 (MS-553: 100 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 200 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 250 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 300 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 350 mg BID) | Phase II Expansion Cohort A2 (MS-553 Monotherapy) | Phase II Expansion Cohort A3 (MS-553 Monotherapy) | Phase I Combination Dose Escalation Cohort B1 (MS-553: 150 mg BID) | Phase I Combination Dose Escalation Cohort B1 (MS-553: 200 mg BID) | Phase I Combination Dose Escalation Cohort C1 (MS-553: 150 mg BID) | Phase I Combination Dose Escalation Cohort C1 (MS-553: 200 mg BID) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Lung infectionInfections and infestations | 0/4 | 0/3 | 0/3 | 0/4 | 2/4 | 1/23 | 0/6 | 0/3 | 1/3 | 0/3 | 0/4 |
| Acute kidney injuryRenal and urinary disorders | 2/4 | 0/3 | 0/3 | 1/4 | 1/4 | 0/23 | 0/6 | 0/3 | 0/3 | 1/3 | 0/4 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/4 | 0/3 | 1/3 | 0/4 | 0/4 | 0/23 | 0/6 | 0/3 | 0/3 | 0/3 | 0/4 |
| Cardiac failureCardiac disorders | 0/4 | 1/3 | 0/3 | 0/4 | 0/4 | 1/23 | 0/6 | 0/3 | 0/3 | 0/3 | 0/4 |
| Myocardial infarctionCardiac disorders | 0/4 | 0/3 | 1/3 | 0/4 | 0/4 | 0/23 | 0/6 | 0/3 | 0/3 | 1/3 | 0/4 |
| PyrexiaGeneral disorders | 0/4 | 0/3 | 1/3 | 1/4 | 1/4 | 3/23 | 0/6 | 0/3 | 0/3 | 0/3 | 1/4 |
| Disease progressionGeneral disorders | 0/4 | 0/3 | 0/3 | 0/4 | 0/4 | 0/23 | 0/6 | 0/3 | 1/3 | 0/3 | 0/4 |
| CholecystitisHepatobiliary disorders | 0/4 | 0/3 | 0/3 | 0/4 | 0/4 | 0/23 | 0/6 | 0/3 | 0/3 | 1/3 | 0/4 |
| Cholecystitis acuteHepatobiliary disorders | 0/4 | 0/3 | 0/3 | 0/4 | 0/4 | 0/23 | 0/6 | 0/3 | 0/3 | 1/3 | 0/4 |
| PneumoniaInfections and infestations | 1/4 | 1/3 | 1/3 | 0/4 | 0/4 | 2/23 | 0/6 | 0/3 | 0/3 | 0/3 | 0/4 |
| Event | Phase I Dose Escalation Cohort A1 (MS-553: 100 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 200 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 250 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 300 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 350 mg BID) | Phase II Expansion Cohort A2 (MS-553 Monotherapy) | Phase II Expansion Cohort A3 (MS-553 Monotherapy) | Phase I Combination Dose Escalation Cohort B1 (MS-553: 150 mg BID) | Phase I Combination Dose Escalation Cohort B1 (MS-553: 200 mg BID) | Phase I Combination Dose Escalation Cohort C1 (MS-553: 150 mg BID) | Phase I Combination Dose Escalation Cohort C1 (MS-553: 200 mg BID) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Anaemias NECBlood and lymphatic system disorders | 4/4 | 3/3 | 0/3 | 0/4 | 3/4 | 5/23 | 0/6 | 0/3 | 2/3 | 0/3 | 1/4 |
| Visual disorders NECEye disorders | 0/4 | 1/3 | 0/3 | 1/4 | 2/4 | 5/23 | 1/6 | 1/3 | 3/3 | 0/3 | 2/4 |
| Diarrhoea (excl infective)Gastrointestinal disorders | 2/4 | 2/3 | 3/3 | 2/4 | 4/4 | 11/23 | 3/6 | 2/3 | 1/3 | 1/3 | 2/4 |
| Nausea and vomiting symptomsGastrointestinal disorders | 4/4 | 2/3 | 3/3 | 2/4 | 3/4 | 17/23 | 2/6 | 2/3 | 3/3 | 2/3 | 4/4 |
| Asthenic conditionsGeneral disorders | 2/4 | 1/3 | 3/3 | 2/4 | 3/4 | 11/23 | 1/6 | 2/3 | 2/3 | 2/3 | 3/4 |
| Platelet analysesInvestigations | 4/4 | 2/3 | 2/3 | 2/4 | 2/4 | 4/23 | 1/6 | 0/3 | 1/3 | 0/3 | 2/4 |
| White blood cell analysesInvestigations | 4/4 | 2/3 | 2/3 | 1/4 | 4/4 | 6/23 | 1/6 | 0/3 | 1/3 | 0/3 | 2/4 |
| Hyperglycaemic conditions NECMetabolism and nutrition disorders | 4/4 | 2/3 | 1/3 | 0/4 | 3/4 | 2/23 | 0/6 | 1/3 | 1/3 | 0/3 | 1/4 |
| Protein metabolism disorders NECMetabolism and nutrition disorders | 4/4 | 1/3 | 0/3 | 0/4 | 2/4 | 2/23 | 0/6 | 0/3 | 1/3 | 0/3 | 0/4 |
| Sodium imbalanceMetabolism and nutrition disorders | 1/4 | 3/3 | 0/3 | 0/4 | 3/4 | 1/23 | 0/6 | 0/3 | 1/3 | 0/3 | 1/4 |
Treated population included all participants who had received at least one dose of the study drug
| Age, Categorical(Participants) | Phase I Dose Escalation Cohort A1 (MS-553: 100 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 200 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 250 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 300 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 350 mg BID) | Phase II Expansion Cohort A2 (MS-553 Monotherapy) | Phase II Expansion Cohort A3 (MS-553 Monotherapy) | Phase I Combination Dose Escalation Cohort B1 (MS-553: 150 mg BID) | Phase I Combination Dose Escalation Cohort B1 (MS-553:200 mg BID) | Phase I Combination Dose Escalation Cohort C1 (MS-553: 150 mg BID) | Phase I Combination Dose Escalation Cohort C1 (MS-553: 200 mg BID) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 1 | 1 | 1 | 0 | 2 | 2 | 1 | 0 | 1 | 2 | 12 |
| >=65 years | 3 | 2 | 2 | 3 | 4 | 21 | 4 | 2 | 3 | 2 | 2 | 48 |
| Sex: Female, Male(Participants) | Phase I Dose Escalation Cohort A1 (MS-553: 100 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 200 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 250 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 300 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 350 mg BID) | Phase II Expansion Cohort A2 (MS-553 Monotherapy) | Phase II Expansion Cohort A3 (MS-553 Monotherapy) | Phase I Combination Dose Escalation Cohort B1 (MS-553: 150 mg BID) | Phase I Combination Dose Escalation Cohort B1 (MS-553:200 mg BID) | Phase I Combination Dose Escalation Cohort C1 (MS-553: 150 mg BID) | Phase I Combination Dose Escalation Cohort C1 (MS-553: 200 mg BID) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 1 | 0 | 1 | 3 | 8 | 1 | 1 | 2 | 0 | 2 | 21 |
| Male | 2 | 2 | 3 | 3 | 1 | 15 | 5 | 2 | 1 | 3 | 2 | 39 |
| Ethnicity (NIH/OMB)(Participants) | Phase I Dose Escalation Cohort A1 (MS-553: 100 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 200 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 250 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 300 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 350 mg BID) | Phase II Expansion Cohort A2 (MS-553 Monotherapy) | Phase II Expansion Cohort A3 (MS-553 Monotherapy) | Phase I Combination Dose Escalation Cohort B1 (MS-553: 150 mg BID) | Phase I Combination Dose Escalation Cohort B1 (MS-553:200 mg BID) | Phase I Combination Dose Escalation Cohort C1 (MS-553: 150 mg BID) | Phase I Combination Dose Escalation Cohort C1 (MS-553: 200 mg BID) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 |
| Not Hispanic or Latino | 4 | 3 | 2 | 4 | 4 | 23 | 6 | 3 | 2 | 2 | 3 | 56 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Phase I Dose Escalation Cohort A1 (MS-553: 100 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 200 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 250 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 300 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 350 mg BID) | Phase II Expansion Cohort A2 (MS-553 Monotherapy) | Phase II Expansion Cohort A3 (MS-553 Monotherapy) | Phase I Combination Dose Escalation Cohort B1 (MS-553: 150 mg BID) | Phase I Combination Dose Escalation Cohort B1 (MS-553:200 mg BID) | Phase I Combination Dose Escalation Cohort C1 (MS-553: 150 mg BID) | Phase I Combination Dose Escalation Cohort C1 (MS-553: 200 mg BID) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| White | 4 | 3 | 2 | 3 | 4 | 23 | 6 | 3 | 2 | 3 | 4 | 57 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 |
| Region of Enrollment(participants) | Phase I Dose Escalation Cohort A1 (MS-553: 100 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 200 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 250 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 300 mg BID) | Phase I Dose Escalation Cohort A1 (MS-553: 350 mg BID) | Phase II Expansion Cohort A2 (MS-553 Monotherapy) | Phase II Expansion Cohort A3 (MS-553 Monotherapy) | Phase I Combination Dose Escalation Cohort B1 (MS-553: 150 mg BID) | Phase I Combination Dose Escalation Cohort B1 (MS-553:200 mg BID) | Phase I Combination Dose Escalation Cohort C1 (MS-553: 150 mg BID) | Phase I Combination Dose Escalation Cohort C1 (MS-553: 200 mg BID) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 4 | 3 | 3 | 4 | 4 | 23 | 6 | 3 | 3 | 3 | 4 | 60 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2018 to primary completion in Nov 2023, 66 months.
Results were first posted in Apr 2025, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PKC-beta Inhibitor MS-553
Leukemia, Lymphocytic, Chronic, B-Cell →
MingSight Pharmaceuticals, Inc